Screener
Allogene Therapeutics ALLO Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's current ratio?
- Allogene Therapeutics (ALLO) reported current ratio of 9.6× in Q1 2026.
- How has Allogene Therapeutics's current ratio changed year-over-year?
- Allogene Therapeutics's current ratio decreased by 0.7% year-over-year, from 9.7× to 9.6×.
- What is the long-term trend for Allogene Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Allogene Therapeutics's current ratio has grown at a -2.4% compound annual growth rate (CAGR), from 9× to 7.9×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.
Ask your AI about Allogene Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude